* If you want to update the article please login/register
Comparing to a historical control group of women with preeclampsia, this research seeks to determine if eculizumab is a safe way to prolong pregnancy in women with preeclampsia. The FDA has approved Eculizumab for the treatment of women with atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria, and it is commonly used in pregnant women with these disorders. According to the investigators, eculizumab can prolong pregnancy in women with preeclampsia diagnosed before 30 weeks gestation with overactive complement. Eculizumab may be a step up from the current standard of care in that it provides a treatment option for patients who could otherwise be managed by expectant management alone. If the research's objectives are met, eculizumab will become a safe treatment option for women with preeclampsia.
Source link: https://clinicaltrials.gov/ct2/show/NCT04725812
Hidradenitis suppurativa is a debilitating chronic inflammatory follicular skin disease that causes debilitating chronic skin disease. In up to 83% of patients receiving an C5a antibody, an open label phase 2 study revealed that a 5 percent HS clinical response rate was achieved in up to 83% of patients receiving a C5a antibody. C5aR's binding to the canonical complement 5a receptor 1a C5aR causes the majority of C5A reactions. We'll use these C5aRi to investigate the various effects of targeting C5aR in this article. Study Design An ex vivo skin culture kit will be used to determine the effects of C5aR inhibition on neutrophil proliferation and inflammation functions. Skin biopsy biopsies of 40 patients with documented Hidradenitis Suppurativa will be extracted from skin excisions of 40 patients. The Surplus skin excision material from HS patients' "deroofment" therapy will be used. These reports will extend the already-running experiments with Dr. Kavita and colleagues, as well as the finding that continuing activation of neutrophils and other C5a-expressing leukocytes in the skin lesions of HS patients contributes to tissue damage. We intend to obtain plasma samples from 40 HS patients with active disease. The plasma samples will also be used to stimulate immune cells isolated from health donors. The C5aR and C5aR inhibitors will be used to determine the role of C5aR in these in vitro assays. Participants will keep their initial study code and collected specimens will be dated and visit number labelled, and re-enrolled participants will keep their initial study code and collected samples will be retained.
Source link: https://clinicaltrials.gov/ct2/show/NCT04251663
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions